Iterion's Tegavivint Targets Previously 'Undruggable' Cancer Pathway

HOUSTON, TX – April 13, 2026 – In the complex and often frustrating war on cancer, some targets have remained stubbornly out of reach. For decades, the Wnt/β-catenin signaling pathway, a fundamental cellular program that goes haywire in an estimated 25-30% of all solid tumors, has been one of oncology's most sought-after yet elusive goals. Now, new data from Iterion Therapeutics suggests a potential breakthrough, offering a novel strategy to attack this pervasive cancer driver.

At the 2026 American Association for Cancer Research (AACR) Annual Meeting, the Houston-based clinical-stage company presented compelling findings on its lead drug candidate, tegavivint. The presentations detailed how this first-in-class small molecule successfully inhibits the Wnt pathway through a unique mechanism, demonstrating potent anti-tumor activity in preclinical models and showing encouraging clinical responses in early human trials. The news signals a potential paradigm shift in treating a wide array of difficult cancers, from hepatocellular carcinoma to colorectal cancer and pediatric osteosarcoma.

Cracking the Wnt Code

The Wnt/β-catenin pathway is a master regulator essential for embryonic development and adult tissue maintenance. In healthy cells, its activity is tightly controlled. In cancer, however, mutations cause the pathway to become constantly active, leading to the accumulation of a protein called β-catenin in the cell's nucleus. This nuclear β-catenin acts as a rogue conductor, switching on a symphony of genes that drive uncontrolled cell proliferation, prevent cell death, and promote tumor growth. The pathway’s dysregulation is a hallmark of many cancers, including over 95% of colorectal cancers.

Despite its clear role in malignancy, the pathway has earned a reputation for being 'undruggable.' The core protein, β-catenin, lacks the typical pockets or enzymatic sites that drugs can easily bind to. Furthermore, earlier attempts to block the pathway by targeting its upstream components often failed due to severe toxicities. Because the Wnt pathway is also crucial for healthy tissues like bone and the gastrointestinal tract, these early drugs caused unacceptable side effects, halting their development.

Iterion's tegavivint sidesteps these historical roadblocks with a novel and elegant approach. Instead of targeting β-catenin directly or interfering with upstream signals, tegavivint targets a previously unexploited downstream partner protein: TBL1. TBL1 is essential for stabilizing β-catenin inside the nucleus and enabling its cancer-promoting gene expression program. By binding to TBL1, tegavivint disrupts this critical partnership. This action effectively marks nuclear β-catenin for degradation, silencing its oncogenic signaling without affecting the pathway's other necessary functions in the cell. This precision targeting is the key to its potentially superior safety profile.

"These data further support our strategy of targeting TBL1 as a novel approach to treating Wnt-driven cancers," said Rahul Aras, Ph.D., President and Chief Executive Officer of Iterion Therapeutics, in a statement. "We see the potential for tegavivint to play an important role across multiple cancers where Wnt signaling drives disease."

Clinical Momentum in Difficult Cancers

The scientific promise of TBL1 inhibition is now being translated into clinical results. Iterion recently completed a Phase 1 study of tegavivint in patients with advanced hepatocellular carcinoma (HCC), a deadly form of liver cancer with limited treatment options. The study, which enrolled heavily pre-treated patients, demonstrated not only a favorable safety and tolerability profile but also encouraging signs of anti-tumor activity.

While full results are forthcoming, previously shared data from the trial (NCT05797805) showed a disease control rate of 63% across all patients. More impressively, among the subset of patients whose tumors had known β-catenin activating mutations—a group notoriously resistant to therapy—the objective response rate was 25% and the disease control rate was a remarkable 88%. These early results suggest that tegavivint is hitting its intended target and having a meaningful clinical effect, particularly in a biomarker-defined patient population.

Buoyed by this success, Iterion is preparing to advance tegavivint into a Phase 2 study for HCC and is strategically expanding its clinical program. The company has initiated a Phase 1 study in Wnt-driven colorectal cancer, another major area of unmet need where the pathway is almost universally activated. One of the posters presented at AACR highlighted tegavivint's potent activity in preclinical colorectal cancer models, providing a strong rationale for its clinical development in this setting.

Hope on the Horizon for Patients

The potential impact of a safe and effective Wnt pathway inhibitor cannot be overstated. For patients with advanced HCC, treatment options are scarce, and prognoses are often poor. Similarly, patients with metastatic colorectal cancer eventually exhaust standard therapies, leaving them with few viable choices. Tegavivint's favorable tolerability profile, with mostly low-grade side effects observed in trials so far, could offer a significant quality-of-life advantage over cytotoxic chemotherapies.

Perhaps most compelling is the drug's potential in rare and pediatric cancers. Iterion is also exploring tegavivint in pediatric osteosarcoma, the most common bone cancer in children and adolescents. The Wnt pathway is a known driver of this aggressive disease, and survival rates have stagnated for decades. In recognition of this critical need, the U.S. FDA has granted tegavivint a Pediatric Rare Disease Designation for osteosarcoma, in addition to an Orphan Drug Designation for desmoid tumors, another Wnt-driven rare disease.

This multi-pronged strategy, backed by $26 million in Product Development Awards from the Cancer Prevention and Research Institute of Texas (CPRIT), positions Iterion at the forefront of Wnt-targeted drug development. The data presented at AACR provides a crucial layer of validation for the TBL1-inhibition strategy, reinforcing the platform's potential. As the company pushes forward with its clinical trials in HCC, colorectal cancer, and osteosarcoma, the oncology community will be watching closely, hopeful that a once-undruggable pathway may finally be brought to heel.